Exhibit 10.1


 


[*] Certain information in this document
has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.


 


SPONSORED RESEARCH AGREEMENT


 


This Sponsored
Research Agreement (“Agreement”) is effective as of the last date of signature on the signature page below (“Effective
Date”) by and between the University of Maryland, Baltimore (“UMB”), a public university of the State
of Maryland, having offices at 620 West Lexington Street, 4th floor, Baltimore, Maryland 21201, and
Silo Pharma, Inc., a Delaware corporation with its principal place of business at 560 Sylvan Ave, Suite 3160, Englewood Cliffs, New Jersey
078632( “Sponsor”).


 


ARTICLE 1 - BACKGROUND


 


1.1 Sponsor
desires the research assistance of persons employed by UMB who have access to UMB facilities and equipment. Accordingly, Sponsor agrees
to fund research entitled “Targeted liposomal drug delivery for rheumatoid arthritis” and described in the protocol
attached as Exhibit A, to be performed by UMB Personnel (defined below).


 


1.2 UMB
and Sponsor entered into a Commercial Evaluation License and Option Agreement as of February 26, 2021 (“CELA”), regarding
UMB’s inventions generally known as “Joint-homing peptides for use on the investigation and treatment of arthritogenic
processes” made by Kamal Moudgil, MD, PhD, and Ying-hua Yang, PhD, both employees of UMB.


 


1.3 UMB
has determined that the research is consistent with its education, research, and public service missions, and is willing to furnish the
research services of UMB Personnel as described in Exhibit A upon the terms and conditions of this Agreement.


 


ARTICLE 2 - DEFINITIONS


 


In this Agreement, the following terms
are defined as stated:


 


2.1 “Arising
IP”: Any invention, discovery, or improvement (whether or not patentable) and any copyrightable work which is made, conceived,
developed, invented, or discovered during and directly in the course of performing the Project Work.


 


2.2 “Confidential
Information”: Information (including without limitation, documents, notes, drawings, models, designs, data, results, memoranda,
tapes, records, hardware, software, formulae, algorithms, standard operating procedures, strategic business plans, product forecasts,
communications with government entities, financial information, pricing information, personnel information, and other commercially sensitive
or proprietary information or materials (in hard copy form or in electronic form), which is disclosed by a party to the other party in
connection with this Agreement.


 


2.3 “Project
Work”: The scope of work as described in Exhibit A to be undertaken by UMB, or by UMB and Sponsor, under this Agreement,
and any amendments to Exhibit A made in accordance with Section 17.3.


 


2.4 “Results”:
Data and results which are generated during and directly in the course of performing the Project Work.


 


2.5 “Sponsor
Affiliate”: Any person or entity that controls, is controlled by, or is under common control with Sponsor. For the purposes
of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under
common control with”) means the ownership, directly or indirectly, whether through one or more intermediaries, of fifty percent
(50%) or more of the equity securities entitled to vote in the election of directors (or, in the case of an entity that is not
a corporation, for the election of the corresponding managing authority).


 






     


     


    

 


2.6 “UMB
Personnel”: The following individuals to the extent that they use UMB resources and are subject to UMB intellectual property
policies (including any prior or future policy): The PI; UMB faculty members; research fellows; students; technicians; scientists; trainees;
and/or other individuals working under the supervision or direction of the PI on the Project Work. “UMB Personnel” will also
include independent contractors, consultants, agents, and representatives of UMB, when those individuals are acting in those capacities.


 


2.7 “UMB
Related Organization”: University System of Maryland, any constituent institution of University System of Maryland, University
of Maryland Medical System, the faculty practice organizations of UMB, and the Baltimore Veterans Administration Medical Center.


 


ARTICLE 3 - PROJECT WORK


 


3.1 UMB
agrees to commence performance of the Project Work promptly after the Effective Date of this Agreement, and will undertake to perform
the Project Work substantially in accordance with the terms and conditions of this Agreement. Sponsor and UMB may amend the Project Work
at any time in accordance with Section 17.3. Each party will work diligently and in good faith to accomplish the goals and objectives
of this Agreement. Any modification to the Project Work will be executed in writing by the duly authorized representative of each Party
and will thereafter, as amended or modified, be incorporated into this Agreement by reference.


 


3.2 The
Principal Investigator (“PI”) for the Project Work is Kamal Moudgil, MD, PhD, an employee of UMB. The Project Work
will be supervised by the PI. If for any reason the PI is unwilling or unable to continue to serve, UMB will notify Sponsor promptly,
and UMB will endeavor to find an acceptable replacement. If a substitute PI acceptable to both UMB and Sponsor is not appointed within
sixty (60) days, this Agreement may be terminated by either party in accordance with Section 8.2 below.


 


ARTICLE 4 - REPORTS AND CONFERENCES


 


4.1 Written
progress reports will be provided by UMB to Sponsor as specific phases of work are completed. A final report will be submitted by UMB
within ninety (90) days after the expiration or termination of this Agreement.


 


4.2 If
necessary during the Term, UMB Personnel may meet with representatives of Sponsor at times and places mutually agreed upon to discuss
the progress and results of the Project Work, as well as ongoing plans, or any changes in the Project Work. To the extent consistent with
UMB policy, Sponsor shall reimburse UMB for travel costs associated with these meetings for the PI and other UMB Personnel invited to
the meetings with Sponsor's approval if such costs have not been included in the approved budget.


 


ARTICLE 5 - COST, BILLINGS, AND
OTHER SUPPORT


 


5.1 Subject
to modifications in the Project Work, the total costs to Sponsor under this Agreement shall not exceed the sum of [*] ($[*] USD). These
costs will be allocated by UMB generally in accordance with the budget incorporated in Exhibit B.


 


5.2 Sponsor shall make payments to UMB in U.S.
Dollars within thirty (30) days upon Sponsor’s receipt of an invoice, as set forth on Exhibits B and C.


 






    	 	2	 



     


    

 





5.3 Sponsor
agrees that it will not make any incentive payments to UMB Personnel or otherwise compensate individual UMB Personnel for their involvement
in performing the Project Work.


 


5.4 Any
dispute of an invoice must be made to UMB in writing and within thirty (30) days of receipt of said invoice.


 


5.5 Any
balance outstanding forty five (45) days after the date payment was due shall bear interest at the rate of one and a half percent (1.5%)
monthly on the unpaid amount. Such interest to begin accruing on the thirty first (31st) day after the date the payment was due. Further,
any payment which is uncontested and not paid in full within 180 days after the date payment was due shall be turned over to the State
Central Collection Unit (SCCU), which shall result in an additional seventeen percent (17%) collection fee, plus any legal fees required,
to be added to the amount due and becoming immediately due and payable.


 


ARTICLE 6 - RESULTS AND PUBLICATIONS


 


6.1 All
Results will be owned by UMB. Until UMB publishes the Results pursuant to this Article 6 (but not later than twenty four (24) months
after the completion of the Project Work):


 


(a) Sponsor
shall treat the unpublished Results as UMB’s Confidential Information; and (b) Sponsor may use the unpublished Results only for
internal research purposes. Following publication of any Results, Sponsor may use any such published Results for any purpose (but the
restrictions of the preceding sentence shall continue to apply to any unpublished Results until the expiration of the twenty four month
period).


 


6.2 Sponsor
acknowledges that UMB and UMB Personnel have an interest in publishing the Results. Notwithstanding anything herein to the contrary, but
subject to the provisions of this Article 6, UMB and UMB Personnel may present the Results at symposia and other professional meetings,
and publish the Results in journals, theses, dissertations, or other publications or presentations of their own choosing.


 


6.3 UMB
shall forward a copy of the proposed publication to Sponsor thirty (30) days in advance of the planned publication date. Sponsor will
treat the copy of the proposed publication as UMB’s Confidential Information. Sponsor’s review of the proposed publication
and its rights regarding the proposed publication will be limited to the following:


 


(a) If
Sponsor determines reasonably and in good faith that the proposed publication contains Sponsor’s Confidential Information, Sponsor
will promptly identify such information to UMB. UMB Personnel will delete such information from the publication as reasonably requested
by Sponsor, and publication may be delayed for a maximum of thirty (30) days for that purpose.


 


(b) If
Sponsor determines reasonably and in good faith that there is patentable subject matter contained in the proposed publication, Sponsor
will promptly identify such subject matter to UMB. If Sponsor reasonably requests a delay in order to file patent applications or otherwise
to protect its intellectual property, the publication may be delayed for a maximum of ninety (90) days for that purpose.


 


6.4 Following
publication by UMB Personnel or UMB, Sponsor may freely publish, reproduce, and use any such publication to the extent that any such
use is consistent with 17 U.S.C. 


§107.


 






    	 	3	 



     


    

 





ARTICLE 7 - INTELLECTUAL PROPERTY


 


7.1 Each
party owns and will continue to own its intellectual property that: (a) exists prior to the Effective Date of this Agreement; or (b) that
is made, conceived, developed, invented, or discovered after the Effective Date of this Agreement but not during and directly in the course
of performing the Project Work (“Background IP”). Neither party has or will have any right, title, or interest in the
other party’s Background IP; provided however, that each party shall have certain rights in the other party’s Background
IP as provided in the CELA. Sponsor’s Background IP is listed in Exhibit D. UMB’s Background IP is listed in Exhibit E. However,
Sponsor hereby grants to UMB a royalty-free, non-exclusive, non-assignable, and non-transferrable license to use Sponsor’s Background
IP during the term of this Agreement for the sole purpose of performing the Project Work, or as otherwise permitted by this Agreement.
Each of the parties will hold in confidence any Background IP of the other party which is included in any Results.


 


7.2 If
UMB and Sponsor execute a master license agreement to UMB Background IP prior to the expiration or termination of the Agreement, the terms
of the master license agreement will supersede.


 


7.3 Sponsor
will own all right, title and interest in and to any Arising IP that is invented, discovered, or made solely by employees or agents of
Sponsor and does not incorporate any UMB Background IP (“Sponsor Arising IP”). UMB will own all right, title and interest
in and to any Arising IP that is invented, discovered, or made solely by UMB Personnel, or by persons otherwise under an obligation to
assign to UMB (“UMB Arising IP”). UMB and Sponsor will jointly own any Arising IP which is invented, discovered, or
made by one or more UMB Personnel (or by persons otherwise under an obligation to assign to UMB) and one or more employees or agents of
Sponsor (“Joint Arising IP”).


 


7.4 UMB
will report promptly to Sponsor in writing all UMB Arising IP or Joint Arising IP that is disclosed to UMB’s Office of Technology
Transfer or its successor during the term of this Agreement. Sponsor will hold in confidence these reports from UMB.


 


7.5 UMB hereby grants
to Sponsor an option to negotiate and obtain an exclusive license to any UMB Arising IP and UMB’s rights in any Joint Arising IP
(the “Option”), provided that there are no uncured defaults or material breaches by Sponsor of this Agreement. The
Option (and the license to be granted upon exercise of the Option) is subject to the provisions of 35 U.S.C. §§ 201 et seq.
and all implementing regulations, if applicable (“Federal IP Policy”), and UMB’s agreements with third parties.


 


7.6 Sponsor
may exercise the Option by giving written notice to UMB within sixty (60) days after Sponsor receives notice from UMB of the relevant
UMB Arising IP or Joint Arising IP. Before receiving such a license, Sponsor must outline its capability and plans to develop and commercialize
products that use the relevant Arising IP, which must be acceptable to UMB in its reasonable discretion. Promptly following UMB’s
receipt of Sponsor’s notice of exercise, the parties will negotiate in good faith for a period of ninety (90) days (the “Negotiation
Period”) the terms of a master license agreement.


 


7.7 The
master license agreement will contain terms and conditions customary to technology licenses normally granted by UMB, including
without limitation terms consistent with the provisions of Federal IP Policy, if applicable; a reservation of the rights of UMB to
practice and to grant other not-for-profit organizations the right to practice the relevant Arising IP for research, teaching and
other educational purposes, and to publish; license fees; royalty payments; milestone payments; reimbursement of patent expenses;
commercially reasonable due diligence obligations; liability limitations; and indemnity and insurance provisions for the benefit of
UMB and UMB Related Organizations.


 






    	 	4	 



     


    

 


7.8 If
the parties are not able to resolve any differences regarding the master license agreement within the Negotiation Period, the parties
will utilize the dispute resolution process set forth in Article 16 to resolve, to the extent reasonably possible, such differences.
Subject to any such dispute resolution, if the parties have not executed a master license agreement before the end of the Negotiation
Period, Sponsor will thereafter have no rights with respect to the relevant Arising IP, and UMB may license all or a portion of such relevant
Arising IP to one or more third parties.


 


7.9 For
purposes of this Agreement, inventorship or authorship of any Arising IP shall be determined solely in accordance with U.S. intellectual
property law, notwithstanding that the laws of other countries where patent, trademark, or copyright applications are filed may differ
from U.S. intellectual property law.


 


ARTICLE 8 - TERM AND TERMINATION


 


8.1 The
term of this Agreement commences as of the Effective Date and the Project Work shall commence on September 1, 2021 and will continue until
the substantial completion of the Project Work (the “Term”), subject to renewal upon mutual written consent of the
parties.


 


8.2 Either
party may terminate this Agreement upon thirty (30) days’ prior written notice to the other party, subject to Section 8.4
below.


 


8.3 In
addition, if either party commits any material breach of or default in any of the terms or conditions of this Agreement, and fails to
remedy that default or breach within ten (10) business days after receipt of written notice from the other party, the party giving notice
may, in its sole but reasonable discretion and in addition to any other remedies which it may have at law or in equity, terminate this
Agreement by sending written notice of termination to the other party to that effect, and such termination will be effective as of the
date of the receipt of that notice.


 


8.4 If
Sponsor terminates this Agreement for any reason other than an uncured material breach by UMB, Sponsor shall relinquish any and all rights
it may have in the Results to UMB.


 


8.5 If
this Agreement is terminated early, Sponsor will pay all costs accrued by UMB as of the effective date of termination and any costs incurred
by UMB as a result of termination. In addition, Sponsor will reimburse UMB for non-cancellable obligations called for by the Project Work
and incurred prior to the effective date of termination.


 


8.6 Expiration
or termination of this Agreement does not relieve either party of any obligation for payment or reporting which arises before expiration
or termination including obligations under Articles 4, 5, and 7. Any provision of this Agreement which contemplates performance
or observance subsequent to any termination or expiration of this Agreement shall survive any termination or expiration of this Agreement
and continue in full force and effect, including without limitation Articles 6, 7, 9, 10, 13, 14, and 17


 






    	 	5	 



     


    

 


ARTICLE 9 - INDEMNIFICATION AND
INSURANCE


 


9.1 UMB
and its officers and employees acting within the scope of their employment by UMB are subject to the Maryland Tort Claims Act, Title
12, Subtitle 1, State Government Article, Annotated Code of Maryland, which permits, under certain circumstances and subject to
limitations provided by law, claims in tort against the State of Maryland related to negligence of UMB employees. In order to file a
claim under the Act, a claimant must submit a written claim to the Treasurer of the State of Maryland or a designee of that office
within one year after the injury to the person or property that is the basis of the claim.


 


9.2 Sponsor
warrants that it maintains a policy or program of insurance or self- insurance at levels sufficient to support the indemnification obligations
assumed herein. A certificate evidencing such coverage will be delivered to UMB upon request.


 


9.3 Sponsor
shall defend, indemnify, and hold harmless UMB, UMB Personnel, UMB Related Organizations, and the State of Maryland, and their respective
regents, officers, employees, students, subcontractors, and agents (each individually a “UMB Party”) against any claim,
liability, cost, damage, deficiency, loss, expense or obligation of any kind or nature (including without limitation reasonable attorneys’
fees, expert witness fees, court costs and other costs and expenses of litigation at trial and appellate levels) incurred by or imposed
upon any UMB Party in connection with any claims, suits, actions, demands or judgments arising directly or indirectly from (a) Sponsor’s
use or reporting of the Results; (b) use of any material or equipment provided by Sponsor resulting in a claim of patent infringement
or violation of proprietary rights against a UMB Party; and/or (c) Sponsor’s negligence, intentional misconduct, or breach of this
Agreement, or that by any Sponsor employee or agent.


 


9.4 The
agreement to defend, indemnify, and hold harmless a UMB Party is conditioned upon: (a) the UMB Party or UMB promptly notifying Sponsor
in writing after the UMB Party receives notice of any claim; provided, however, the failure to so notify Sponsor will not relieve
Sponsor of any obligation which it may have to a UMB Party under this Agreement or otherwise, to the extent that such failure or delay
does not actually and materially prejudice Sponsor; and (b) the UMB Party cooperating with Sponsor in the defense of the claim (but at
Sponsor’s expense). The agreement to defend, indemnify, and hold harmless a UMB Party will not apply to the extent that the claim,
cost, or liability was solely caused by the negligence or intentional misconduct of that UMB Party. Notwithstanding the foregoing, each
UMB Party will have the right to participate at its own expense in the defense of any claims through counsel of its own choosing. Sponsor
will not settle any claim in any manner that affects a UMB Party’s rights without that UMB Party’s prior written consent,
which will not be unreasonably withheld, conditioned, or delayed.


 


9.5 UMB
and Sponsor further agree that nothing in this Agreement will be interpreted as: (a) a denial to either party of any remedy or defense
available to it under the laws of the State of Maryland; (b) the consent of the State of Maryland or its agents, agencies, or instrumentalities
to be sued; or (c) a waiver of sovereign immunity or any other governmental immunity of the State of Maryland and UMB beyond the extent
of any waiver provided by law.


 


ARTICLE 10 – CONFIDENTIALITY


 


Any Confidential Information shall be subject to the terms
of Exhibit F.


 






    	 	6	 



     


    

 


ARTICLE 11 - PUBLICITY


 


11.1 Neither
Sponsor nor UMB will use the name, seal, logo, trademark, or service mark of the other or the name of any employee, student, or
Affiliate (or in the case of UMB, UMB Related Organization) of the other, or any adaptation thereof, in any advertising,
promotional, or sales literature without obtaining the prior written consent from the other party (and such consent will not be
unreasonably withheld), individual, affiliate or organization, as the case may be, except that consent will not be required where a
disclosure is required by applicable law or regulation.


 


11.2 Each
party may publicize the fact that the parties have entered into this Agreement in its business development documentation and/or its website.
However, press releases or other public releases of information will be approved in writing by the parties prior to release, except where
that disclosure is required by applicable law or regulation.


 


11.3 UMB
does not directly or indirectly endorse any product or service provided or to be provided by Sponsor, its successors, assigns, or sublicensees
by entering into this Agreement or otherwise. Sponsor shall not in any way advertise, publicize, or imply that UMB endorses any of those
products or services.


 


ARTICLE 12 - NOTICES


 


All notices, consents
and other communications required or allowed under this Agreement must be in writing and are effective upon receipt: (a) when delivered
by hand with proof of delivery; or (b) when received by the addressee after being mailed by registered or certified mail (air mail if
mailed overseas), return receipt requested; or (c) when received by the addressee by express delivery service (return receipt requested),
in each case addressed to the party at its address set forth below (or to another address that a party may later designate by notice to
the other party):


 


	 	If to UMB:	Associate Vice President, 

CCT Office of Research and Development University of Maryland, 

Baltimore 620 West Lexington Street, 4th floor Baltimore, 

Maryland 21201-1508
	 	 	 
	 	Copy to:	University Counsel
	 	 	University of Maryland, Baltimore 220 Arch Street, Room 03-111
	 	 	Baltimore, Maryland 21201-1531
	 	 	 
	 	If to Sponsor:	Eric Weisblum, CEO
	 	 	Silo Pharma, Inc.
	 	 	560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632
	 	 	 
	 	Copy to:	Richard A Friedman, Esq.
	 	 	Sheppard Mullin
	 	 	30 Rockefeller Plaza
	 	 	New York, NY 10112-0015



 






    	 	7	 



     


    

 


ARTICLE 13 - FEDERAL REQUIREMENTS


 


13.1 The
use and disclosure of technical information acquired pursuant to this Agreement and the use of patent rights under any licenses
granted under the terms of this Agreement are subject to the export, assets, and financial control regulations of the United States
of America, including, but not limited to, restrictions under regulations of the United States that may be applicable to direct or
indirect re-exportation of such technical information or of equipment, products, or services directly produced by use of such
technical information. Sponsor is responsible for taking any steps necessary to comply with such regulations.


 


13.2 If
Arising IP is made with equipment or facilities funded in whole or in part by agencies of the United States government or embody or are
dependent upon background intellectual property funded in whole or in part by agencies of the United States government, products of Sponsor
for use or sale in the United States that embody Arising IP or are produced through the use of Arising IP shall be manufactured substantially
in the United States.


 


ARTICLE 14 - STATE REQUIREMENTS


 


14.1 Sponsor
will not knowingly employ or compensate, directly or indirectly, any UMB Personnel working on matters related to the Project Work or involved
in negotiating this Agreement on behalf of UMB, during employment by UMB or for two (2) years thereafter, unless consented in writing
by UMB’s President (or his/her designee); provided, however, that nothing in this Section 14.1 will prohibit Sponsor from
hiring any UMB Personnel who respond to general employment solicitation not targeted at UMB Personnel, including general advertisement.
“Compensation” includes without limitation: stock option or stock purchase agreements, consulting agreements, any other form
of agreement, and cash payments. “Employment” includes both uncompensated and compensated service. The Maryland Public Ethics
Law (Title 5, General Provisions Article, Annotated Code of Maryland) may apply to a decision by the UMB President in regard to the matter.


 


14.2 This
Article 14 is not intended to prevent UMB Personnel from (a) serving on Sponsor’s scientific advisory board; (b) conducting
the Project Work or performing research pursuant to a sponsored research agreement between Sponsor and UMB; or (c) serving as a consultant
to or performing any work for Sponsor for a fee. However, all of those cases are subject to and contingent upon compliance with the conflict
of interest and other provisions of the Maryland Public Ethics Law, and with applicable policies and procedures of University System of
Maryland and UMB, including without limitation those regarding consulting arrangements.


 


14.3 During
the Term, UMB will not knowingly employ or compensate, directly or indirectly, any officers, directors, and employees of Sponsor working
on matters related to the Project Work or involved in negotiating this Agreement on behalf of Sponsor, during employment by Sponsor or
for two (2) years thereafter, unless consented in writing by Sponsor; provided, however, that nothing in this Article 14 will prohibit
UMB from hiring any officer, director, or employee of Sponsor who responds to general employment solicitation not targeted at him or her,
including general advertisement.


 


ARTICLE 15 - INTEGRATION AND
SEVERABILITY


 


15.1 This
Agreement, together with any Exhibits specifically referenced and attached, embodies the entire understanding between Sponsor and UMB.
There are no contracts, understandings, conditions, warranties or representations, oral or written, express or implied, with reference
to the subject matter of this Agreement that are not merged in this Agreement.


 


15.2 If
any condition or provision in this Agreement is held to be unenforceable by a court of competent jurisdiction, then that condition
or provision will be modified to the minimum extent necessary to make it enforceable, unless that modification is not permitted by
law, in which case the condition or provision will be disregarded. If an unenforceable condition or provision is modified or
disregarded in accordance with this Section, then the rest of the Agreement will remain in effect as written.


 






    	 	8	 



     


    

 


ARTICLE 16 - DISPUTE RESOLUTION


 


16.1 If
a dispute between the parties related to this Agreement arises, either party, by notice to the other party, may have the dispute referred
to the parties’ respective officers designated below, or their successors, for attempted resolution by good faith negotiations within
thirty (30) days after the notice is received. The designated officers are as follows:


 


For Sponsor: CEO


 


For UMB: Chief Enterprise and Economic
Development Officer and Vice President


 


16.2 If
the designated officers are not able to resolve the dispute within this thirty (30) day period, or any agreed extension, they will confer
in good faith with respect to the possibility of resolving the matter through mediation with a mutually acceptable third party or a national
mediation organization. If the parties agree to attempt to resolve the matter through mediation, they will participate in any mediation
sessions in good faith in an effort to resolve the dispute in an informal and inexpensive manner. All expenses of the mediator will be
shared equally by the parties.


 


16.3 Any
applicable statute of limitations will be tolled during the pendency of a dispute resolution procedure initiated under this Agreement.
Evidence of anything said or any admission made in the course of any dispute resolution procedure will not be admissible in evidence in
any civil action between the parties. In addition, no document prepared for the purpose of, or in the course of, or pursuant to, the dispute
resolution procedure, or copy thereof, will be admissible in evidence in any civil action between the parties. However, the admissibility
of evidence will not be limited if all parties who participated in the dispute resolution procedure consent to disclosure of the evidence.


 


16.4 With
respect to any dispute that is not resolved pursuant to other provisions of this Article 16, each party consents to the jurisdiction
of the Circuit Court of Baltimore City or Anne Arundel County, Maryland for any suit against the other party relating to this Agreement,
and agrees to file any such suit in one of those courts. THE PARTIES WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY LITIGATION BETWEEN THEM
RELATING TO THIS AGREEMENT.


 


16.5 No
provision of this Agreement will constitute or be construed as a limitation, abrogation, or waiver of any defense or limitation of liability
available to the State of Maryland or its units (including without limitation USM and UMB), officials, or employees under Maryland or
Federal law, including without limitation the defense of sovereign immunity or any other governmental immunity.


 


16.6 LIMITATION
OF LIABILITY. NO PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, PUNITIVE OR INCIDENTAL DAMAGES
(INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF A DULY AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED
OF THE POSSIBILITY OR LIKELIHOOD OF SAME.


 






    	 	9	 



     


    

 





ARTICLE 17 - MISCELLANEOUS


 


17.1 This
Agreement is made and will be construed in accordance with the laws of the State of Maryland without regard to the principles of conflicts
of laws.


 


17.2 Neither
party may assign this Agreement in whole or in part without the prior written consent of the other party, which consent shall not be unreasonably
withheld. Any assignment in violation of this Agreement shall be null and void.


 


17.3 This
Agreement, including Exhibits, may not be amended, nor may any right or remedy of either party be waived, unless the amendment or waiver
is in writing and signed by a duly authorized representative of each party.


 


17.4 Neither
party is liable for failure or delay in performing any of its obligations under this Agreement if the failure or delay is required in
order to comply with any governmental regulation, request or order, or necessitated by other circumstances beyond the reasonable control
of the party so failing or delaying, including but not limited to Acts of God, war (declared or undeclared), insurrection, fire, flood,
accident, labor strikes, work stoppage or slowdown (whether or not such labor event is within the reasonable control of the parties),
or inability to obtain raw materials, supplies, power or equipment necessary to enable a party to perform its obligations. Each party
shall: (a) promptly notify the other party in writing of an event of force majeure, the expected duration of the event and its anticipated
effect on the ability of the party to perform its obligations; and (b) make reasonable efforts to remedy the event of force majeure.


 


17.5 UMB
and Sponsor are not (and nothing in this Agreement may be construed to constitute them as) partners, joint venturers, agents, representatives,
or employees of the other, nor is there any status or relationship between them other than that of independent contractors. Neither party
has any responsibility nor liability for the actions of the other party except as specifically provided in this Agreement. Neither party
has any right or authority to bind or obligate the other party in any manner or make any representation or warranty on behalf of the other
party.


 


17.6 This
Agreement is not intended to create, and does not create, enforceable legal rights as a third party beneficiary or through any other legal
theory on the part of any UMB Personnel or any other person except as expressly provided within this Agreement.


 


17.7 This
Agreement may be signed in duplicate originals. The headings used in this Agreement are for convenience of reference only and do not affect
the meaning or construction of this Agreement.


 


17.8 Each
party has participated in the negotiations and drafting for the Agreement. Therefore, in the event of any ambiguity in the wording of
this Agreement, the ambiguity shall not be construed against any particular party as the drafter of the ambiguous provision.


 


17.9 The
parties will execute and deliver and cause to be executed and delivered further agreements, instruments, and document and will take further
actions as may reasonably be required or appropriate to carry out the terms and conditions of this Agreement.


 


[Signature page follows]


 






    	 	10	 



     


    

 


SIGNATURE PAGE TO SPONSORED
RESEARCH AGREEMENT



 


IN WITNESS WHEREOF, each party has caused
this Agreement to be executed by its duly authorized representatives on the dates indicated below.


 


	SILO PHARMA, Inc.	 
	 	 	 
	By:	/s/ Eric Weisblum	 
	Name: 	Eric Weisblum	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	7/6/2021	 
	 	 	 
	UNIVERSITY OF MARYLAND, BALTIMORE	 
	 	 	 
	By:	/s/ Michael A. Rollor, Ph.D.	 
	 	Michael A. Rollor, Ph.D.	 
	 	Associate Vice President	 
	 	Center for Clinical Trials and Corporate Contracts	 



 


Date: 7/6/2021


 


I have reviewed the Agreement and Exhibits and I understand
and acknowledge the responsibilities of the Principal Investigator.


 


	/s/ Kamal Moudgil, MD, PhD	 
	Kamal Moudgil, MD, PhD 

Principal Investigator	 
	 	 
	Date: 7/6/2021	 



 






     


     


    

 


EXHIBIT A


 


PROJECT WORK


 


[*]


 






     


     


    

 





EXHIBIT B


 


BUDGET


 


[*]


 






     


     


    

 


EXHIBIT C


 


PAYMENT INFORMATION


 


[*]


 






     


     


    

 





EXHIBIT D


 


Sponsor Background Intellectual
Property


 


[Intentionally omitted]


 






     


     


    

 





EXHIBIT E


 


UMB Background Intellectual Property


 


[*]


 






     


     


    

 


EXHIBIT F


 


STANDARD CONFIDENTIALITY PROVISIONS


 


[*]